Company Overview
WW International, Inc. provides weight management products and services in the United States, Germany, Canada, and internationally. It offers various nutritional, activity, behavioral, and lifestyle tools and approaches for individual weight goals, as well as for people taking GLP-1 medications or living with diabetes, as well as offers guidance and medication access for women reaching perimenopause and menopause. The company also provides Core, a digital subscription product for weight loss and weight management; Core+ tier, a subscription for unlimited access to workshops; and Med+ subscription tier provides unlimited access to a clinician who can prescribe medications when clinically appropriate, including oral and injectable GLP 1s and hormone replacement therapy. In addition, it licenses its trademarks and other intellectual property in food, beverages, and other weight management-relevant consumer products and services, as well as provides publishing services. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019. WW International, Inc. was founded in 1963 and is headquartered in New York, New York.
Why Investors Should Care
Return on capital employed stands at 140.8%.
Net profit has compounded at 520.4% per year over the last five years.
Trades at a P/E of 1.6, below the sector median of 27.4.
Recent Developments
- Dec 2025 Revenue of $710.64M (-9.6% YoY); net profit $1.06B.
- Trailing 12 Months Year-on-year growth — revenue -9.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -10.6%, profit CAGR 520.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -10.62% |
| 1 Year: | -9.80% |
Compounded Profit Growth
| 5 Years: | 520.36% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -66.60% |
| 6 Months: | -31.72% |
| 3 Months: | +36.37% |
| 1 Month: | -11.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.56 · Neutral
P/E of 1.57 is below the sector median of 27.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 140.8%.
- Profit CAGR of 520.4% over 5 years.
CONS
- Revenue declined at -10.6% CAGR over 5 years.
- Trading 68.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WW WW International, Inc. | 14.36 | 1.57 | $143.58M | 0.00% | 140.80% | - | -10.62% | 520.36% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 186.57M | 177.00M | 184.26M | 162.81M | 168.26M |
| Cost of Revenue | - | 53.70M | 46.49M | 51.24M | 48.72M | 49.59M |
| Gross Profit | - | 132.88M | 130.51M | 133.02M | 114.09M | 118.67M |
| Operating Expenses | - | 125.53M | 89.10M | 122.40M | 127.03M | 148.58M |
| Operating Income | - | 7.35M | 41.40M | 10.62M | -12.94M | -29.91M |
| EBITDA | - | -15.49M | 1.19B | 36.52M | 13.39M | -3.82M |
| Interest Expense | - | 27.60M | 11.06M | 12.97M | 11.77M | 11.47M |
| Pretax Income | - | -50.01M | 1.17B | -3.63M | -24.69M | -41.18M |
| Tax Provision | - | 22.57M | -20.91M | 52.63M | -18.86M | 10.82M |
| Net Income | - | -72.58M | 1.19B | -56.26M | -5.83M | -52.00M |
| Diluted EPS | - | -0.91 | - | -5.63 | - | -5.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 889.55M | 785.92M | 710.64M |
| Cost of Revenue | 360.25M | 252.82M | 200.14M |
| Gross Profit | 529.30M | 533.10M | 510.50M |
| Operating Expenses | 503.34M | 454.29M | 464.06M |
| Operating Income | 25.97M | 78.81M | 46.43M |
| EBITDA | 74.73M | -198.44M | 1.22B |
| Interest Expense | 95.89M | 108.95M | 63.41M |
| Pretax Income | -73.63M | -345.18M | 1.09B |
| Tax Provision | 38.62M | 526.00K | 35.45M |
| Net Income | -112.25M | -345.70M | 1.06B |
| Diluted EPS | -1.46 | -4.34 | 7.58 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 550.28M | 946.76M |
| Current Assets | 102.65M | 213.60M |
| Cash & Equivalents | 53.02M | 160.28M |
| Inventory | - | - |
| Receivables | 14.43M | 16.38M |
| Total Liabilities | 1.66B | 628.69M |
| Current Liabilities | 173.33M | 126.54M |
| Long Term Debt | 1.43B | 465.47M |
| Total Debt | 1.48B | 468.62M |
| Total Equity | -1.11B | 318.07M |
| Shares Outstanding | 9.99M | 9.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 6.69M | -16.84M | -28.90M |
| Investing Cash Flow | -74.70M | -16.41M | -19.50M |
| Financing Cash Flow | -2.75M | -17.34M | 153.90M |
| Capital Expenditure | -36.30M | -16.41M | -17.48M |
| Free Cash Flow | -29.61M | -33.25M | -46.38M |
| Net Change in Cash | -70.76M | -50.60M | 105.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 59.5% | 67.8% | 71.8% |
| Operating Margin % | 2.9% | 10.0% | 6.5% |
| Net Margin % | -12.6% | -44.0% | 148.6% |
| ROE % | - | 31.0% | 332.0% |
| ROCE % | - | 20.9% | 5.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cooper Creek Partners Management LLC | 9.76% | 975.42K | $14.01M |
| 2 | Fund 1 Investments, LLC | 7.80% | 779.63K | $11.20M |
| 3 | Aristeia Capital, LLC | 7.49% | 748.48K | $10.75M |
| 4 | Millennium Management Llc | 6.48% | 648.38K | $9.31M |
| 5 | Carronade Capital Management, Lp | 4.57% | 456.72K | $6.56M |
| 6 | UBS Group AG | 3.16% | 315.71K | $4.53M |
| 7 | Contrarius Group Holdings Ltd | 3.07% | 307.17K | $4.41M |
| 8 | Blackrock Inc. | 2.72% | 271.87K | $3.90M |
| 9 | AEGON USA Investment Management, LLC | 2.30% | 230.12K | $3.30M |
| 10 | JPMORGAN CHASE & CO | 2.19% | 219.28K | $3.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WW
WW — Frequently Asked Questions
What is the current share price of WW International, Inc. (WW)?
As of 2026-08-02 19:16 PDT, WW International, Inc. (WW) trades at $14.36 on NasdaqGM. Its 52-week range is $9.12 to $44.89.
What is the market capitalisation of WW?
WW International, Inc. (WW) has a market capitalisation of $143.58M on NasdaqGM.
What is the P/E ratio of WW?
WW trades at a trailing price-to-earnings (P/E) ratio of 1.57. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 0.45.
Is WW a good stock to buy?
This page provides a data-driven analysis of WW International, Inc. (WW), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.